Histopathological and immunohistochemical diagnosis of advanced medullary breast carcinoma: case report / Diagnóstico histopatológico e imuno-histoquímico de carcinoma medular avançado de mama: relato de caso

Ricardo Barbosa Lima, Simone Yuriko Kameo, Andressa Cabral Vassilievitch, Tiago Vasconcelos Fonseca, Bruno Ferreira Amorim, Jéssica dos Santos Costa, Glebson Moura Silva, Namie Okino Sawada


Medullary breast carcinoma (CMM) is a rare histological variant of breast cancer. It is a malignant and invasive tumor often observed in young women with large tumor lesions. There are still controversies about survival rates, about the histological pattern and prognosis of the CMM. The aim of this case report is to explain the histopathological diagnosis of a patient diagnosed with advanced medullary breast carcinoma, with emphasis on immunohistochemical findings. In a private oncology service, a 57-year-old woman came for treatment. At the initial clinical examination, it was observed that it presented a necrosis-like right breast tumor, firm on palpation and painful symptoms. An incisional lesion biopsy was performed and the cellular and molecular pattern traced. The report found the presence of advanced medullary breast carcinoma, necrotic malignant lesion in stage IV with bone and renal metastasis. The morphological pattern was composed of large epithelioid cells with pleomorphic and often multinucleated nuclei, with irregular chromatin distribution and atypical mitosis figures. The observed molecular pattern was focal expression of cytokeratin AE1 / AE3, smooth muscle actin, desmin, p63 and CD68. Additionally, the expressions of estrogen receptors, CD34, S-100 and CK8/18 were not observed. The tumor was unresectable and chemotherapy and radiotherapy was chosen to intervene in the disease progression, however, the patient died due to clinical complications resulting from these treatments associated with poor general health. CMM is a rare neoplasm and immunohistochemical studies may contribute to understand how morphological and molecular patterns may influence its clinical presentation.


Delayed Diagnosis, Breast Neoplasms, Medullary Carcinoma, Medical Oncology, Prognosis

Full Text:



Instituto Nacional do Câncer (Brasil). Estimativa 2018: Incidência de câncer no Brasil. Rio de Janeiro: INCA; 2018.

Netra SM, Vani BR, Murthy VS. Cytomorphological Study of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma. J Cytol. 2018 Oct-Dec; 35(4): 195–198. Available from: https://dx.doi.org/10.4103%2FJOC.JOC_160_17.

Aksoy A, Odabas H, Kaya S, Bozkurt O, Degirmenci M, Topcu TO, et al. Hormone receptor status and survival of medullary breast cancer patients. Saudi Med J. 2017 Feb; 38(2): 156–162. Available from: https://dx.doi.org/10.15537%2Fsmj.2017.2.18055.

Zangouri V, Akrami M, Tahmasebi S, Talei A, Hesarooeih AG. Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study. Iran J Med Sci. 2018 Jul; 43(4): 365–371.Aailable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055214.

Park I, Kim J, Kim M, Bae SY, Lee SK, Kil WH, et al. Comparison of the Characteristics of Medullary Breast Carcinoma and Invasive Ductal Carcinoma. J Breast Cancer. 2013 Dec; 16(4): 417–425. Available from: https://dx.doi.org/10.4048%2Fjbc.2013.16.4.417.

Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, et al. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012 Nov;23(11):2843-51. Available from: https://doi.org/10.1093/annonc/mds105.

Lim ST, Park SH, Park HK, Hur HM, Oh SJ, Suh YJ. Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population. PLoS One. 2015; 10(11): e0140208. Available from: https://dx.doi.org/10.1371%2Fjournal.pone.0140208.

Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget. 2016 Apr 19;7(16):22665-73. Available from: https://doi.org/10.18632/oncotarget.8142.

Cao AY, He M, Huang L, Shao ZM, Di GH. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified. World J Surg Oncol. 2013 Apr 22;11:91. Available from: https://doi.org/10.1186/1477-7819-11-91.

Romaniuk A, Lyndin M, Sikora V2, Lyndina Y, Panasovska K. Histological and immunohistochemical features of medullary breast cancer. Folia Med Cracov. 2015;55(2):41-8. Available from: http://www.fmc.cm-uj.krakow.pl/pdf/55_2_41.pdf.

Sohn YM, Han K, Seo M. Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors. Iran J Radiol. 2016 Jul 4;13(4):e31386. Available from: https://doi.org/10.5812/iranjradiol.31386.

Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist. 2014 Aug;19(8):805-13. Available from: https://doi.org/10.1634/theoncologist.2014-0108.

Rechsteiner M, Dedes K, Fink D, Pestalozzi B, Sobottka B, Moch H, et al. Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. J Cancer Res Clin Oncol. 2018 May;144(5):865-874. Available from: https://doi.org/10.1007/s00432-018-2609-5.

Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YH, de Boer L, et al. Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget. 2016 Sep 27;7(39):63537-63548. Available from: https://doi.org/10.18632/oncotarget.11535.

Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Oncotarget. 2015 Oct 13;6(31):32115-37. Available from: https://doi.org/10.18632/oncotarget.5617.

DOI: https://doi.org/10.34119/bjhrv3n2-021


  • There are currently no refbacks.